Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.
Corresponding to one of the two groups below:
* Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
* Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment
Affiliation to a social security scheme
Patient who signed the genetic consent form
You may not be if
Minor patient
Pregnant patient
Patient under guardianship or conservatorship
Patients who object to the collection of their medical/paramedical data
Patient for whom the center does not have biological material for genomic analysis (FFPE block)
Patient under administrative, judicial decision or AME (State Medical Aid)
Clareo Health | Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
